Search form
Search
Login
Subscribe
Home
Country Intelligence
Industry Directory
Offsets / IC
Tenders
Australia
(21/week)
Haiti
(0/week)
Guyana
(0/week)
Honduras
(0/week)
Guatemala
(0/week)
View all
(21/week)
News
United States
(578/week)
Manufacturing
(398/week)
Energy
(304/week)
Technology
(413/week)
Environment
(238/week)
Events
About us
Who we are
Our People
Partners
Contact us
LinkedIn
Login
Twitter
Register
Home
News
Biohaven Pharmaceutical Holding Company Ltd.
Dec 10, 2018
Biohaven Announces Positive Results from Ongoing Rimegepant Long-Term Safety Study
Dec 10, 2018
Biohaven Announces Proposed Public Offering of Common Shares
Dec 03, 2018
Biohaven Delivers Positive Phase 3 Results with Rimegepant Zydis® Orally Dissolving Tablet (ODT): Rapid and Lasting Benefit for the Acute Treatment of Migraine
Nov 28, 2018
Biohaven Announces Formation Of BioShin, A Wholly Owned Asia-Pacific Subsidiary
Nov 26, 2018
Biohaven Announces FDA Acceptance of 505(b)(2) NDA Filing for BHV-0223, a Novel Sublingual Delivery Form of Riluzole for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
Nov 20, 2018
Biohaven Pharmaceuticals to Host Inaugural Research & Development Day on November 26, 2018
Nov 15, 2018
Biohaven Enrolls First Patient In Phase 3 Preventive Treatment Of Migraine Trial With Its Oral CGRP Receptor Antagonist Rimegepant
Nov 14, 2018
Biohaven Pharmaceuticals Reports Third Quarter 2018 Financial And Recent Business Results
Oct 22, 2018
Biohaven Receives Authorization to Proceed from FDA and Doses First Subject with BHV-3500, Third-Generation, Small Molecule CGRP-Receptor Antagonist
Oct 09, 2018
Biohaven Acquires Option To License Biologic Investigational Agent For Inflammatory And Autoimmune Diseases From The University of Connecticut
Sep 12, 2018
Biohaven Appoints Bob Repella to Board of Directors
Sep 12, 2018
Biohaven Announces Submission of IND for BHV-3500, Third-Generation, Small Molecule CGRP-Receptor Antagonist for the Treatment of Migraine
Sep 06, 2018
Biohaven Presents at Migraine Trust International Symposium and Highlights Positive Results from Study 301 and Study 302 of Rimegepant, an Oral CGRP Receptor Antagonist, in the Acute Treatment of Migraine
Sep 05, 2018
Biohaven Licenses Novel Myeloperoxidase Inhibitor From AstraZeneca: Potential First-In-Class Treatment For Multiple System Atrophy
Aug 16, 2018
Biohaven Reports Positive Results From Double-Blind, Placebo-Controlled, Investigator Initiated, Proof Of Concept Trial Of BHV-0223 For Anxiety
Aug 14, 2018
Biohaven Pharmaceuticals Reports Second Quarter 2018 Financial And Recent Business Results
Aug 01, 2018
First Patient Enrolled In Biohaven's Phase 2/3 Mild-To-Moderate Alzheimer's Clinical Trial
Jul 24, 2018
Biohaven Receives FDA May Proceed Letter And Initiates Phase 2/3 Clinical Trial Of Trigriluzole (BHV-4157) In Alzheimer's Disease
Jun 28, 2018
Biohaven Expands Rimegepant Development Program to Include New Prevention of Migraine Phase 3 Trial and Highlights Key Late-Breaking Presentations at American Headache Society (AHS) Annual Scientific Meeting
Jun 18, 2018
Biohaven And Royalty Pharma Announce Royalty Funding And Stock Purchase Agreements Totaling $150 Million
‹‹
Page 5
››
Latest News
Apr 25, 2024
Asahi Kasei to Construct a Lithium-ion Battery Separator Plant in Canada
Apr 25, 2024
Getech Engaged by East Star Resources to Locate Porphyry Copper in Kazakhstan
Apr 25, 2024
Helix Reports First Quarter 2024 Results
Apr 25, 2024
Mativ Announces Appointment of New Chair of its Board of Directors
Apr 25, 2024
Leading Industry Publication: Black & Veatch Remains Among Global Critical Infrastructure Leaders as...
Apr 25, 2024
WM Announces First Quarter 2024 Earnings
Apr 25, 2024
Oceaneering Reports First Quarter 2024 Results
Apr 25, 2024
NewMarket Corporation Reports First Quarter 2024 Results
View all News
Agenda
17
June
France
Parc des Expositions de Paris Nord Villepinte ZAC Paris Nord 2, 93420 Villepinte – France (Halls 5a – 5b – 6)
Eurosatory 2024, 17 - 21 June 2024, Parc des Expositions de Paris Nord Villepinte ZAC Paris Nord 2, 93420 Villepinte – France (Halls 5a – 5b – 6)
Eurosatory 2024 There can be no sustainable world without peace and security. Founded in 1967, the exhibition...
21
May
Paris Marriott Rive Gauche & Conference Center
Future Artillery, 21-23 May 2024, Paris Marriott Rive Gauche & Conference Center, France
DELIVERING FIRES IN THE MULTI-DOMAIN BATTLESPACE As artillery reasserts itself as the ‘King of Battlefield’ in the wake...
21
May
United Arab Emirates
ADNEC (Abu Dhabi National Exhibition Centre), Abu Dhabi, Al Khaleej Al Arabi St - Al Rawdah - Al Ma'arid - Abu Dhabi, UAE
ISNR Abu Dhabi 2024, 21-23 May 2024, ADNEC (Abu Dhabi National Exhibition Centre), Abu Dhabi, Al Khaleej Al Arabi St - Al Rawdah - Al Ma'arid - Abu Dhabi, UAE
ISNR ACCELERATING TRANSFORMATION IN THE NATIONAL SECURITY ECOSYSTEM ISNR Abu Dhabi is the region’s most trusted...
View All Events